FDA Bans Imports from Ranbaxy’s Toansa Plant, Daiichi Sankyo Promises Full Cooperation with FDA

The US FDA said on January 23 that it will ban Ranbaxy Laboratories, a subsidiary of Daiichi Sankyo, from manufacturing and distributing US-bound active pharmaceutical ingredients (APIs) from its plant in northern India. Daiichi Sankyo apologized in its press release...read more